Floatz logo

Olanzapine

Attention Deficit-Hyperactivity

Washington University School of MedicineSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Attention Deficit-Hyperactivity cohort.

Asset / SponsorPhaseRating
Methylphenidate
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 4BBB
Mixed Salts Amphetamine
University of Cincinnati
Phase 4BB
Methylphenidate
St. Jude Children's Research Hospital
Phase 4BB
Lis-Dexamphetamine
Duke University
Phase 4B
Dextromethorphan
Prof. Dr. Frank Behrens
Phase 2CCC

View all 11 →

Same molecule, other indications

Olanzapine is also rated in:

schizophreniform disorderDormant
A
Indicative ·
83 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →